Skip to Content

Newsletter No. 37 -- August, 2000

ITEMS OF INTEREST TO THE IMAGING RESEARCH COMMUNITY:

CIP Web Site: http://www.cancer.gov/bip

NIH

  1. SMALL ANIMAL IMAGING RESOURCE PROGRAMS (CA-01-012)
    Letter of Intent Receipt Date: October 19, 2000; Application Receipt Date: November 28, 2000 The National Cancer Institute (NCI) invites applications from extramural and intramural investigators for Small Animal Imaging Resource Programs (SAIRPs). These grants will support (a) shared imaging research resources to be used by cancer investigators, (b) research related to small animal imaging technology, and (c) training of both professional and technical support personnel interested in the science and techniques of small animal imaging. SAIRPs will enhance capabilities for conducting basic, clinical, and translational cancer research relevant to the mission of the NCI. Major goals of this initiative are to increase efficiency, synergy, and innovation of such research and to foster research interactions that cross disciplines, approaches and levels of analysis. Building and strengthening such links holds great potential for better understanding cancer, and ultimately, for better treatment and prevention. This request for applications is a reissue of RFA CA-98-023, which was released in the NIH Guide of August 20, 1998.
    URL: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-01-012.html
  2. DEVELOPMENT OF CLINICAL IMAGING DRUG ENHANCERS (DCIDE) (NCI) (Notice:CA-00-018)
    Developers of new imaging compounds should take special notice of the NCI's new DCIDE program, based on the RAID program of the Developmental Therapeutics Program (see RAID on the sidebar of http://dtp.nci.nih.gov/ for developments in the RAID program). DCIDE will make available to investigators, on a competitive basis, the preclinical development contract resources of NCI. The goal of DCIDE is the development of promising imaging molecular probes or enhancers (contrast agents) that are otherwise unlikely to undergo further development leading to Investigational New Drug (IND) application. The latest FDA draft Guidance document, entitled "Guidance for Industry: Developing Medical Imaging Drugs and Biological Products" is available at http://www.fda.gov/cder/guidance/3646dft.pdf
    URL: http://cancer.gov/bip/dcide.htm

___________________________________

The Cancer Imaging Program at NCI has created this e-mail distribution list to notify interested people about funding opportunities and other issues related to imaging research. Its primary purpose is to call your attention to important, relevant information on NIH Web pages, or in the NIH Guide. Occasionally it may be used to clarify areas of confusion, or disseminate answers to frequently asked questions.

If you wish to remain on the list, no action is necessary. If you wish to be added to the list (or removed from it), please contact Ms. Johnnie Smith by return e-mail (js95x@nih.gov).

Cancer Imaging Program
Division of Cancer Treatment and Diagnosis, NCI
EPN, Room 6000 - MSC-7412
6130 Executive Boulevard
Bethesda, MD 20892-7440
Tel: 301 496 9531
Fax: 301 480 3507